{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:22:22Z","timestamp":1774981342577,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.semarthrit.2016.03.014","type":"journal-article","created":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T23:49:52Z","timestamp":1459554592000},"page":"253-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Racial disparities in the risk of Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States"],"prefix":"10.1016","volume":"46","author":[{"given":"Na","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharan K.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano E.","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2016.03.014_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/M14-0227","article-title":"Cost-effectiveness of allopurinol and febuxostat for the management of gout","volume":"161","author":"Jutkowitz","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib2","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jamainternmed.2015.3546","article-title":"Reducing life-threatening allopurinol hypersensitivity","volume":"175","author":"Stern","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib3","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib4","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib5","doi-asserted-by":"crossref","first-page":"e94294","DOI":"10.1371\/journal.pone.0094294","article-title":"Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population","volume":"9","author":"Saokaew","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice. Gout","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrrheum.2014.32","article-title":"Optimizing current treatment of gout","volume":"10","author":"Rees","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib11","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1001\/jama.2014.14484","article-title":"Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England","volume":"312","author":"Kuo","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11926-010-0154-6","article-title":"Quality of care in patients with gout: why is management suboptimal and what can be done about it?","volume":"13","author":"Edwards","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2016.03.014_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kep086","article-title":"New insights into the epidemiology of gout","volume":"48","author":"Doherty","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrrheum.2015.94","article-title":"Gout: why compare the effectiveness of suboptimal gout management?","volume":"11","author":"Dalbeth","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib15","unstructured":"\u3008https:\/\/clinicaltrials.gov\/\u3009."},{"key":"10.1016\/j.semarthrit.2016.03.014_bib16","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib19","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib20","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib21","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib24","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2217\/pgs.11.131","article-title":"Allopurinol pharmacogenetics: assessment of potential clinical usefulness","volume":"12","author":"Zineh","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib26","unstructured":"\u3008http:\/\/www.allelefrequencies.net\/\u3009."},{"key":"10.1016\/j.semarthrit.2016.03.014_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/bmj.295.6596.457","article-title":"Migration and gout: the Tokelau Island migrant study","volume":"295","author":"Prior","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib28","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","article-title":"Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning","volume":"129","author":"Patel","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib29","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/rheumatology\/kem273","article-title":"Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample","volume":"46","author":"Chung","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib30","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.22469","article-title":"Gout, urate-lowering therapy, and uric acid levels among adults in the United States","volume":"67","author":"Juraschek","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib31","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib32","unstructured":"\u3008https:\/\/www.hcup-us.ahrq.gov\/team\/NationwideDUA.jsp\u3009."},{"key":"10.1016\/j.semarthrit.2016.03.014_bib33","first-page":"324","article-title":"Essence of the revised guideline for the management of hyperuricemia and gout","volume":"55","author":"Yamanaka","year":"2012","journal-title":"Japan Med Assoc J"},{"key":"10.1016\/j.semarthrit.2016.03.014_bib34","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","article-title":"Improving cardiovascular and renal outcomes in gout: what should we target?","volume":"10","author":"Richette","year":"2014","journal-title":"Nat Rev Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901721630004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901721630004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T01:38:23Z","timestamp":1557365903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901721630004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S004901721630004X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.03.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727303303.793528710","asserted-by":"object"}]},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Racial disparities in the risk of Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}